11. GLP-1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies

  1. Minghan Wang
  1. Remy Burcelin1,
  2. Cendrine Cabou1,
  3. Christophe Magnan2,3 and
  4. Pierre Gourdy1

Published Online: 8 APR 2011

DOI: 10.1002/9780470910016.ch11

Metabolic Syndrome: Underlying Mechanisms and Drug Therapies

Metabolic Syndrome: Underlying Mechanisms and Drug Therapies

How to Cite

Burcelin, R., Cabou, C., Magnan, C. and Gourdy, P. (2011) GLP-1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies, in Metabolic Syndrome: Underlying Mechanisms and Drug Therapies (ed M. Wang), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470910016.ch11

Editor Information

  1. Metabolic Disorders Research, Amgen, Inc., Thousand Oaks, CA, USA

Author Information

  1. 1

    Rangueil Institute of Molecular Medicine, INSERM U858, Toulouse, France

  2. 2

    INSERM U858, Toulouse, France

  3. 3

    University Paris Diderot, CNRS, Paris, France

Publication History

  1. Published Online: 8 APR 2011
  2. Published Print: 14 FEB 2011

ISBN Information

Print ISBN: 9780470343425

Online ISBN: 9780470910016

SEARCH

Keywords:

  • drug targets for antidiabetic therapies - GLP-1 biology, signaling mechanisms, physiology, and clinical studies;
  • main molecular pathways for GLP-1 action - involving insulin secretion and β-cell survival;
  • effects on dyslipidemia - role of GLP-1-based therapies in dyslipidemia

Summary

This chapter contains sections titled:

  • Introduction

  • Origin of the Incretin Concept

  • From the Proglucagon Gene to Protein and Secretion

  • The GLP-1 Receptor

  • Physiological Role of GLP-1

  • Ectopic Effects of GLP-1

  • Central Effects of GLP-1

  • The GLP-1 Dependent Gut-to-Brain-to-Periphery Axis

  • Cardiovascular Effects

  • Effects on Dyslipidemia

  • Secretion

  • Clinical Studies

  • Conclusions

  • References